Home / 2020 / June / 05

Daily Archives: June 5, 2020

COVID-19: Screening test first before prison for detainees, convicts

Each remand detainee or convicts to be sent to the prison in the future will undergo COVID-19 health screening tests, said Inspector-General of Police Tan Sri Abdul Hamid Bador.

 

He said the matter would be co-ordinated with the Ministry of Health (MOH) in an effort to prevent the spread of the pandemic from the outside world into prisons.

 

“I have discussed this with the Malaysian Prison Department’s director-general Datuk Seri Zulkifli Omar and he had asked that all detainees to be sent to prison to undergo COVID-19 tests.

“That is the only precautionary measure we can take,” he told reporters after attending the hand over ceremony of the new patrol vehicles for the Royal Malaysian Police (PDRM) at the Ministry of Home Affairs here today.

 

Abdul Hamid said it was learned that the inmate who tested positive at the Sungai Buloh prison recently has been in the prison since 2016 and had never been out or the  prison or mixed with people from outside.

 

‘’The inmate was sent to the court three months ago, and when he came back, he tested positive, so we don’t know how he got infected,” he explained.

 

 

Last Monday, Bernama reported that MOH had carried out the COVID-19 screenings on more than 800 inmates and 700 employees from the Sungai Buluh Prison after a non-citizen prisoner tested positive for the pandemic.

 

Source: BERNAMA News Agency

PENJANA to ensure recovery of tourism sector – Minister

The National Economic Recovery Plan (PENJANA) to address the challenges faced by industry players in the wake of the COVID-19 outbreak is proof that the government is concerned about helping the recovery of the economic sector especially tourism.

 

Tourism, Arts and Culture Minister Datuk Seri Nancy Shukri said the plan announced by Prime Minister Tan Sri Muhyiddin Yassin today would ensure tourism, arts and culture industry players could continue to contribute to the country.

 

“The initiative for this purpose clearly proves that the Prime Minister is concerned about the plight of the people. Thank you Prime Minister.

 

 

 

“The tourism sector is listed under prohibited economic activities during the Conditional Movement Control Order (CMCO) and the extending of the Wage Subsidy Programme benefits workers, entrepreneurs and operators who have to take unpaid leave,” she said in a statement.

 

Through PENJANA, government has allocated RM9 billion to benefit three million workers in dealing with unemployment.

 

The allocation includes extending the Wage Subsidy Programme introduced in the Prihatin Rakyat Economic Stimulus Package (PRIHATIN) and PRIHATIN additional measures with an additional allocation of RM5 billion.

 

 

Nancy said the RM1 billion Tourism Financing Scheme to finance transformation initiatives by small and medium enterprises (SME) has also helped the tourism sector to stay competitive in the new era.

 

She said the tax deferment initiatives under the tourism businesses such as travel agencies, hoteliers and airlines have been postponing the instalment of the estimated tax for another three months from Oct 1 to Dec 31, 2020.

 

Tourism tax exemptions from July 1, 2020 to June 30, 2021 are also announced, and the exemption from payment of service tax to any person staying or receiving any taxable services provided by the accommodation premises operator will be extended from Sept 1 to June 30, 2021.

 

In addition, individual income tax relief of up to RM1,000 on domestic travel expenses will be extended until Dec 31, 2021, she added.

 

 

Source: BERNAMA News Agency

Elderly businessman fined RM2,500 for using fake ‘Datuk’ title

The Magistrate’s Court here today imposed a RM2,500-fine on an elderly businessman for using a fake ‘Datuk’ title.

 

Mohsin Bujang, 62, pleaded guilty after the charge was read out to him through a court interpreter in the presence of Magistrate Erry Shahriman Nor Aripin.

 

According to the charge, Mohsin was accused of using the title ‘Datuk’ for business, trade, work and professional purposes without written approval from the Federal or state governments.

 

 

 

He was accused of committing the offence at a condominium in Section 13 here at 6.18 p.m., on April 15, 2019.

 

He was charged under Section 3(1)(a) of the  Emblems and Names (Prevention of Improper Use) Act 1963 and could be sentenced under Section 5 of the same act, which provides for a fine of up to  RM20,000 or jail up to three years, or both, if convicted.

 

According to the facts of the case, Mohsin as chief executive of his own company signed a letter to another company using the title ‘Datuk’ which raised doubts with the representative of that company.

 

 

The representative then conducted a check and found no records that Mohsin had received such an award and lodged a police report.

 

Earlier, deputy public prosecutor Muhammad Uzair Abd Munir urged the court to impose a deterrent sentence on the accused as cases of the use of false titles were rampant and would mar the good name of the institution of royalty in the country.

 

Erry Shahriman then imposed a fine of RM2,500 and three months’ jail if the accused failed to pay the fine.

 

The accused paid the fine.

 

Source: BERNAMA News Agency

 

Country not ready to run general election now– Dr Mahathir

 

PUTRAJAYA Malaysia is not ready to hold a general election in view of unfavourable conditions in the country, and the focus should now be on containing the COVID-19 pandemic, said former Prime Minister Tun Dr Mahathir Mohamad.

 

“Some say we should have an election now…but at this moment the country is not fit for an election because we cannot campaign, cannot have crowds and do what we used to do during elections,” he said, adding that an election would also be costly.

 

Speaking in a press conference at the Perdana Leadership Foundation here today, Dr Mahathir said if the attention was diverted towards holding an election, some people would suffer.

 

 

 

Asked if he has the majority support to return as prime minister, Dr Mahathir said he does not know as “the number keep on appearing and disappearing”.

 

On his relationship with PKR president Datuk Seri Anwar Ibrahim, Dr Mahathir said he does not have any problems with Anwar but added: “maybe he has a problem with me, that you (reporters) need to ask him.”

 

 

Source: BERNAMA News Agency

KEMAS childcare centres expected to reopen July 1

 

KUALA LUMPUR The Community Development Department (KEMAS) is expecting its childcare centres to reopen on July 1 and is now awaiting a final decision from the Ministry of Health (MOH).

 

KEMAS director-general Datuk Mohd Yasid Bidin said today there were 520 KEMAS childcare centres throughout Malaysia involving approximately 9,000 staff and children.

 

He said the reopening of these centres was intended to ease parents who wanted to leave their children while at work, but if parents were hesitant, they did not have to do so.

 

 

 

“We do not reopen expecting every parent to drop their children here, we are only providing a facility so that they would have a peace of mind. If we reopen and only a handful of parents send their children here, we will still accept,” he said after the launch of MERCY Malaysia’s PPE sewing project in collaboration with Kemas and Maybank Foundation here.

 

Commenting on the standard operating procedure (SOP) for sending children to the childcare centres, Mohd Yasid said parents should make sure they and their children are healthy and fit.

 

The teachers will also conduct body temperature checks on the children and parents will not be allowed into the premises, he said.

 

Source: BERNAMA News Agency

MCO: Air Selangor to readjust water bills

KUALA LUMPUR Pengurusan Air Selangor Sdn Bhd (Air Selangor) will be making the necessary readjustments for the water bills which were based on the average water consumption during the Movement Control Order (MCO) between March and May.

 

“The total adjustments will be reflected in either the June or July 2020 bill.

 

“If a payment has been made on an overcharged bill during the MCO, the excess amount will be recorded in the customer’s account,” it said.

 

 

 

Air Selangor expects the adjustment to be completed by July 2020.

 

The company will also be providing customers with a better understanding of the new billing mechanics via infographics on its social media accounts.

 

Air Selangor resumed onsite meter reading at customers’ premises since May 2, and has taken into record their actual water consumption after sending out bills in March and April based on estimated readings.

 

 

For queries regarding higher than usual water bill amount, customers can directly contact Air Selangor at 15300, or WhatsApp at 019-280 0919 or 019-281 6793, or reach out via social media (Facebook, Twitter and Instagram), or the Air Selangor application and email at wecare@airselangor.com.

 

 

Source: BERNAMA News Agency

Novavax Awarded Department of Defense Contract for COVID-19 Vaccine

  • $60 million funding for manufacturing of NVX-CoV2373
  • 10 million doses to be delivered to DoD in 2020

GAITHERSBURG, Md., June 04, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the company has been awarded a contract by the U.S. Department of Defense (DoD) for the manufacturing of NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate. NVX‑CoV2373 consists of a stable, prefusion protein antigen made using its proprietary nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant.

JPEO-CRBND-EB through funding provided by the Defense Health Program, has agreed to fund up to $60 million to support Novavax in its production of several components of the vaccine that will be manufactured in the U.S. The agreement includes a 2020 delivery of 10 million doses of NVX‑CoV2373 for DoD that could be used in Phase 2/3 clinical trials or under an Emergency Use Authorization (EUA) if approved by the U.S. FDA.

“We are genuinely honored at the opportunity to protect our military personnel and their families who have devoted themselves to the needs of U.S. citizens and others worldwide,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “Importantly, this award will allow Novavax to significantly expand its U.S. production capacity of NVX-CoV2373, a critical step in our ability to provide vaccine support to the COVID-19 pandemic.”

As part of the contract, Novavax will work with a U.S.-based biologics contract development manufacturing organization (CDMO) to manufacture the antigen component of NVX-CoV2373 for at least 10 million doses of vaccine. Novavax will also collaborate with U.S.-based CDMOs to scale up production and manufacture of the Matrix-M adjuvant component of the vaccine.

About the JPEO-CBRND

The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense is the Joint Service’s lead for development, acquisition, fielding and life-cycle support of chemical, biological, radiological and nuclear defense equipment and medical countermeasures. As an effective acquisition program, we put capable and supportable systems in the hands of the service members and first responders, when and where it is needed, at an affordable price. Our vision is a resilient Joint Force enabled to fight and win unencumbered by a chemical, biological, radiological, or nuclear environment; championed by innovative and state-of-the-art solutions. JPEO Enabling Biotechnologies (EB) is an organization established for the purpose of providing medical solutions, during a crisis, against future threats.

About NVX-CoV2373

NVX‑CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS‑CoV‑2, the virus that causes COVID-19 disease. NVX‑CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. In preclinical trials, NVX‑CoV2373 demonstrated indication of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection. A Phase 1 clinical trial of NVX‑CoV2373 initiated in May 2020, with preliminary immunogenicity and safety results expected in July 2020. The Coalition for Epidemic Preparedness Innovations (CEPI) is investing up to $388 million of funding to advance clinical development of NVX‑CoV2373.

About Matrix-M™

Novavax’ patented saponin-based Matrix-M™ adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products, including statements regarding the manufacturing of vaccine antigen dose amounts and timing, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (SEC) and updated by any Quarterly Report on Form 10-Q, particularly the risks inherent to developing novel vaccines. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts:

Investors
Novavax, Inc.
Erika Trahan
ir@novavax.com
240-268-2022

Westwicke
John Woolford
john.woolford@westwicke.com
443-213-0506

Media
Brandzone/KOGS Communication
Edna Kaplan
kaplan@kogspr.com
617-974-8659